Powder: -20°C for 3 years
In solvent: -80°C for 2 years
LHF-535 is an antiviral compound. It has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.
Description | LHF-535 is an antiviral compound. It has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively. |
In vitro | LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 inhibits Lassa GP-pseudotyped lentivirus (IC50: 0.1-0.3 nM). LHF-535 shows effective antiviral activity against a broad array of hemorrhagic fever arenaviruses [2]. |
In vivo | An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection. LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protects mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver [2]. |
Molecular Weight | 412.52 |
Formula | C27H28N2O2 |
CAS No. | 1450929-77-7 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 96.67 mg/mL (234.34 mM), Need ultrasonic
H2O: < 0.1 mg/mL (insoluble)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LHF-535 1450929-77-7 免疫与炎症 微生物学 Antiviral Virus Protease inhibit Arenavirus LHF 535 Inhibitor LHF535 inhibitor